Merck also turned down the opportunity to profit billions by getting in on the cov vax band wagon. They stated from the start they thought the mRNA would have serious adverse reactions and that they would instead focus on treatments for those suffering from the vax. I think they already had the treatment.
So there needs to be a great deal of sould searching and investigation at Merck, Sanofi, and GSK as to what went wrong.
Because this won't be the last time a virus or disease will required a rapid and precise response in a short time frame.
They either need to change or perish.
Lior Goldberg
25 January, 2021
Replying to AI Dober
Nobody is required to invent vaccines for you unless contracted specifically.
So go soul search why didn't you crowd-fund Merck vaccine division in the past 10 years.
William Summit
25 January, 2021
Replying to Lior Goldberg
Merck looks foolish when you have the likes of Moderna able to develop a vaccine, with NVAX closing in, as well. They look old, slow, and inflexible. It is not a good look.
"Merck said it would continue to develop its two experimental Covid-19 therapeutics. Full results from a Phase 3 study of one of the drugs, called MK-7110, are expected this quarter. A Phase 2/3 study of the other drug, an antiviral called molnupiravir that Merck is developing in collaboration with a privately-held firm called Ridgeback"
Merck also turned down the opportunity to profit billions by getting in on the cov vax band wagon. They stated from the start they thought the mRNA would have serious adverse reactions and that they would instead focus on treatments for those suffering from the vax. I think they already had the treatment.
do you have a source for this? amazing if true!
https://www.barrons.com/articles/merck-scraps-covid-19-vaccine-programs-51611581161
comment section on that article won't age well:
AI Dober 25 January, 2021
Lior Goldberg 25 January, 2021
Replying to AI Dober
William Summit 25 January, 2021
Replying to Lior Goldberg
"Merck said it would continue to develop its two experimental Covid-19 therapeutics. Full results from a Phase 3 study of one of the drugs, called MK-7110, are expected this quarter. A Phase 2/3 study of the other drug, an antiviral called molnupiravir that Merck is developing in collaboration with a privately-held firm called Ridgeback"
Compare the inventor (freely gave it away with apparently no strings attached) to, say, Bill Gates.